senate Bill S4054

2017-2018 Legislative Session

Establishes the sickle cell treatment act of 2017; appropriation

download bill text pdf

Sponsored By

Current Bill Status -


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

do you support this legislation?

You must fill out the form below in order to support or oppose this bill. X

You must login or fill out the fields below for the senator to have an accurate account of the support or opposition to this bill.

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.
Use this box to enter a message to your senator.

Actions

view actions (3)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Feb 14, 2017 print number 4054a
amend and recommit to finance
Feb 02, 2017 referred to finance

Co-Sponsors

view additional co-sponsors

S4054 - Details

Law Section:
Social Services Law
Laws Affected:
Amd §365, Soc Serv L; add Art 31 Title 4 §3126, Pub Health L
Versions Introduced in Previous Legislative Sessions:
2015-2016: S3256B
2013-2014: S6239A

S4054 - Summary

Furnishes preventive medicine to those with sickle cell, establishes prevention and treatment of sickle cell disease programs, and makes an appropriation thereto.

S4054 - Sponsor Memo

S4054 - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  4054

                       2017-2018 Regular Sessions

                            I N  S E N A T E

                            February 2, 2017
                               ___________

Introduced  by Sens. SANDERS, DILAN, HAMILTON, LATIMER, PARKER, PERKINS,
  PERSAUD -- read twice and ordered printed,  and  when  printed  to  be
  committed to the Committee on Finance

AN  ACT  to  amend the social services law and the public health law, in
  relation to establishing the sickle cell treatment act  of  2017;  and
  making an appropriation therefor

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. This act shall be known and may be  cited  as  the  "sickle
cell treatment act of 2017".
  S  2.  Legislative findings. The legislature hereby finds and declares
the following:
  (1) Sickle cell disease (SCD) is an inherited  disease  of  red  blood
cells and is a major health problem in the United States.
  (2) Approximately 100,000 Americans have SCD with approximately 10% of
SCD  patients residing in New York state (NYS).  In NYS, 1 in 1,146 live
births have sickle cell disease, with 12% of  NYS  sickle  cell  disease
births  in the Hispanic population. Higher birth rates for children with
sickle cell disease in NYS occur in mothers born outside of  the  United
States.    Approximately 1,000 American babies are born with the disease
each year. SCD also is a global problem with  close  to  500,000  babies
born annually with the disease.
  (3)  In the United States, SCD is most common in African-Americans and
in those of Hispanic, Mediterranean, and Middle Eastern ancestry.  Among
newborn  American  infants  nationally, SCD occurs in approximately 1 in
500 African-Americans, 1 in 36,000 Hispanics, and  1  in  80,000  Cauca-
sians.    In  NYS, sickle cell disease occurs in 1 in 230 live births to
non-Hispanic black mothers, 1 in 2,320 births to Hispanic mothers and  1
in 41,647 births to Caucasian mothers.
  (4)  More than 3,000,000 Americans, mostly African-Americans, have the
sickle cell trait. These Americans are carriers of the sickle cell  gene

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD01308-01-7

Co-Sponsors

view additional co-sponsors

S4054A (ACTIVE) - Details

Law Section:
Social Services Law
Laws Affected:
Amd §365, Soc Serv L; add Art 31 Title 4 §3126, Pub Health L
Versions Introduced in Previous Legislative Sessions:
2015-2016: S3256B
2013-2014: S6239A

S4054A (ACTIVE) - Summary

Furnishes preventive medicine to those with sickle cell, establishes prevention and treatment of sickle cell disease programs, and makes an appropriation thereto.

S4054A (ACTIVE) - Sponsor Memo

S4054A (ACTIVE) - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 4054--A

                       2017-2018 Regular Sessions

                            I N  S E N A T E

                            February 2, 2017
                               ___________

Introduced  by Sens. SANDERS, DILAN, HAMILTON, LATIMER, PARKER, PERKINS,
  PERSAUD, STAVISKY -- read twice and ordered printed, and when  printed
  to  be  committed to the Committee on Finance -- committee discharged,
  bill amended, ordered reprinted as amended  and  recommitted  to  said
  committee

AN  ACT  to  amend the social services law and the public health law, in
  relation to establishing the sickle cell treatment act  of  2017;  and
  making an appropriation therefor

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. This act shall be known and may be  cited  as  the  "Sickle
Cell Treatment Act of 2017".
  S  2.  Legislative findings. The legislature hereby finds and declares
the following:
  (1) Sickle cell disease (SCD) is an inherited  disease  of  red  blood
cells  and  the  CDC  (Centers for Disease Control) states that SCD is a
major public health concern. Approximately  1,000  American  babies  are
born  with the disease each year, while globally 500,000 babies are born
annually with the disease.
  (2) Sickle cell disease affects approximately 100,000 Americans and is
most common in African-Americans as well as those of Hispanic,  Mediter-
ranean  and  Middle Eastern ancestry. Nationally, SCD occurs in approxi-
mately 1:500 African-Americans, 1:36,000 Hispanics and  1:80,000  Cauca-
sians.  However, in NYS (New York State) SCD occurs in 1:230 live births
to non-Hispanic black mothers, 1:2,320 births to  Hispanic  mothers  and
1:41,647 Caucasian mothers.
  (3)  Approximately  10% of SCD patients reside in NYS. In NYS, 1:1,146
live births have sickle cell  disease,  with  12%  of  NYS  sickle  cell
disease  births  in  the Hispanic population. Higher birth rates for SCD
occur in mothers who were born outside of the US. In NYS,  approximately
80% of sickle cell disease patients live in the NYC area.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD01308-03-7

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.